Cloud Hosting

June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 6473 (2018).

Article CAS PubMed PubMed Central Google Scholar

Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 15071517 (2014).

Article PubMed PubMed Central Google Scholar

Marin, D. et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial. Nat. Med. 30, 772784 (2024).

Article CAS PubMed PubMed Central Google Scholar

Leidner, R. et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N. Engl. J. Med. 386, 21122119 (2022).

Article CAS PubMed PubMed Central Google Scholar

Ghorashian, S. et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat. Med. 25, 14081414 (2019).

Article CAS PubMed Google Scholar

Narayan, V. et al. PSMA-targeting TGF-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat. Med. 28, 724734 (2022).

Article CAS PubMed PubMed Central Google Scholar

Albelda, S. M. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat. Rev. Clin. Oncol. 21, 4766 (2024).

Article PubMed Google Scholar

Parente-Pereira, A. C. et al. Synergistic chemoimmunotherapy of epithelial ovarian cancer using ErbB-retargeted T cells combined with carboplatin. J. Immunol. 191, 24372445 (2013).

Article CAS PubMed Google Scholar

Lee, Y. G. et al. Modulation of BCL-2 in both T cells and tumor cells to enhance chimeric antigen receptor T-cell immunotherapy against cancer. Cancer Discov. 12, 23722391 (2022). This study demonstrated that drug resistance mutations can enable CAR T cell combination therapy with venetoclax.

Article CAS PubMed PubMed Central Google Scholar

Valton, J. et al. A multidrug-resistant engineered CAR T cell for allogeneic combination immunotherapy. Mol. Ther. 23, 15071518 (2015).

Article CAS PubMed PubMed Central Google Scholar

Wu, X. et al. Combined antitumor effects of sorafenib and GPC3-CAR T cells in mouse models of hepatocellular carcinoma. Mol. Ther. 27, 14831494 (2019).

Article CAS PubMed PubMed Central Google Scholar

Wang, A. X., Ong, X. J., DSouza, C., Neeson, P. J. & Zhu, J. J. Combining chemotherapy with CAR-T cell therapy in treating solid tumors. Front. Immunol. 14, 1140541 (2023).

Article CAS PubMed PubMed Central Google Scholar

Gill, S. et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 6, 57745785 (2022).

Article CAS PubMed PubMed Central Google Scholar

Grosser, R., Cherkassky, L., Chintala, N. & Adusumilli, P. S. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell 36, 471482 (2019).

Article CAS PubMed PubMed Central Google Scholar

Rezaei, R. et al. Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy. Cancer Gene Ther. 29, 647660 (2022).

Article CAS PubMed Google Scholar

Tebas, P. et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370, 901910 (2014).

Article CAS PubMed PubMed Central Google Scholar

Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816821 (2012).

Article CAS PubMed PubMed Central Google Scholar

Anzalone, A. V., Koblan, L. W. & Liu, D. R. Genome editing with CRISPRCas nucleases, base editors, transposases and prime editors. Nat. Biotechnol. 38, 824844 (2020).

Article CAS PubMed Google Scholar

Doudna, J. A. The promise and challenge of therapeutic genome editing. Nature 578, 229236 (2020).

Article CAS PubMed PubMed Central Google Scholar

Wang, J. Y. & Doudna, J. A. CRISPR technology: a decade of genome editing is only the beginning. Science 379, eadd8643 (2023).

Article CAS PubMed Google Scholar

Gao, C. Genome engineering for crop improvement and future agriculture. Cell 184, 16211635 (2021).

Article CAS PubMed Google Scholar

Cai, P., Gao, J. & Zhou, Y. CRISPR-mediated genome editing in non-conventional yeasts for biotechnological applications. Microb. Cell Fact. 18, 63 (2019).

Article PubMed PubMed Central Google Scholar

Wellhausen, N., Agarwal, S., Rommel, P. C., Gill, S. I. & June, C. H. Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapy. Curr. Opin. Immunol. 74, 7684 (2022).

Article CAS PubMed Google Scholar

Katti, A., Diaz, B. J., Caragine, C. M., Sanjana, N. E. & Dow, L. E. CRISPR in cancer biology and therapy. Nat. Rev. Cancer 22, 259279 (2022).

Article CAS PubMed Google Scholar

Zhang, L. et al. The construction of drug-resistant cancer cell lines by CRISPR/Cas9 system for drug screening. Sci. Bull. 63, 14111419 (2018).

Article CAS Google Scholar

Ma, L. et al. CRISPR-Cas9mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy. Proc. Natl Acad. Sci. USA 114, 1175111756 (2017).

Article CAS PubMed PubMed Central Google Scholar

Wellhausen, N. et al. Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy. Sci. Transl. Med. 15, eadi1145 (2023). This work demonstrated, for the first time, that CD45 can be druggable without haematopoietic toxicity by engineering the targeted epitope on CD45 in HSCs, thus enabling anti-CD45-directed therapies as universal blood cancer therapies.

Article CAS PubMed PubMed Central Google Scholar

Qasim, W. Genome-edited allogeneic donor universal chimeric antigen receptor T cells. Blood 141, 835845 (2023).

Article CAS PubMed Google Scholar

Casirati, G. et al. Epitope editing enables targeted immunotherapy of acute myeloid leukaemia. Nature 621, 404414 (2023). This work demonstrated, for the first time, that engineering epitopes of functionally relevant cell surface receptors can prevent on-target, off-tumour toxicities of CAR T cells.

Article CAS PubMed PubMed Central Google Scholar

Marone, R. et al. Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy. J. Exp. Med. 220, e20231235 (2023).

Article CAS PubMed PubMed Central Google Scholar

Mondal, N. et al. Non-genotoxic conditioning for hematopoietic stem cell transplant through engineered stem cell antibody paired evasion (ESCAPE). Blood 142, 7128 (2023).

Article Google Scholar

Khorashad, J. S. et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitorresistant CML: frequency and clonal relationships. Blood 121, 489498 (2013).

Article CAS PubMed PubMed Central Google Scholar

Yun, C.-H. et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl Acad. Sci. USA 105, 20702075 (2008).

Article CAS PubMed PubMed Central Google Scholar

Woyach, J. A. et al. Resistance mechanisms for the Brutons tyrosine kinase inhibitor ibrutinib. N. Engl. J. Med. 370, 22862294 (2014).

Article PubMed PubMed Central Google Scholar

Awad, M. M. et al. Acquired resistance to crizotinib from a mutation in CD74ROS1. N. Engl. J. Med. 368, 23952401 (2013).

Article CAS PubMed Google Scholar

Robinson, D. R. et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 45, 14461451 (2013).

Article CAS PubMed PubMed Central Google Scholar

Fresquet, V., Rieger, M., Carolis, C., Garca-Barchino, M. J. & Martinez-Climent, J. A. Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. Blood 123, 41114119 (2014).

Article CAS PubMed Google Scholar

Blombery, P. et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 9, 342353 (2019).

Article CAS PubMed Google Scholar

Sotillo, E. et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 5, 12821295 (2015).

Article CAS PubMed PubMed Central Google Scholar

ORourke, D. M. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. 9, eaaa0984 (2017).

Article PubMed PubMed Central Google Scholar

Sorrentino, B. P. et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR 1. Science 257, 99103 (1992). This work demonstrated, for the first time, the concept of engineering selective drug resistance in HSCs.

Article CAS PubMed Google Scholar

Neff, T., Beard, B. C. & Kiem, H.-P. Survival of the fittest: in vivo selection and stem cell gene therapy. Blood 107, 17511760 (2006).

Article CAS PubMed PubMed Central Google Scholar

Bunting, K. D., Galipeau, J., Topham, D., Benaim, E. & Sorrentino, B. P. Transduction of murine bone marrow cells with an MDR1 vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in transplanted mice. Blood 92, 22692279 (1998).

Article CAS PubMed Google Scholar

Davis, B. M., Ko, O. N. & Gerson, S. L. Limiting numbers of G156A O6-methylguanineDNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection. Blood 95, 30783084 (2000).

Article CAS PubMed Google Scholar

Zielske, S. P., Reese, J. S., Lingas, K. T., Donze, J. R. & Gerson, S. L. In vivo selection of MGMT (P140K) lentivirustransduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning. J. Clin. Invest. 112, 15611570 (2003).

Article CAS PubMed PubMed Central Google Scholar

Nivens, M. C. et al. Engineered resistance to camptothecin and antifolates by retroviral coexpression of tyrosyl DNA phosphodiesterase-I and thymidylate synthase. Cancer Chemother. Pharmacol. 53, 107115 (2004).

Article CAS PubMed Google Scholar

Fu, D., Calvo, J. A. & Samson, L. D. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat. Rev. Cancer 12, 104120 (2012).

Article CAS PubMed PubMed Central Google Scholar

Nathansen, J. et al. Beyond the double-strand breaks: the role of DNA repair proteins in cancer stem-cell regulation. Cancers 13, 4818 (2021).

Article CAS PubMed PubMed Central Google Scholar

Harkey, M. A., Czerwinski, M., Slattery, J. & Kiem, H.-P. Overexpression of glutathione-S-transferase, MGSTII, confers resistance to busulfan and melphalan. Cancer Invest. 23, 1925 (2005).

Article CAS PubMed Google Scholar

Sldek, N. E., Kollander, R., Sreerama, L. & Kiang, D. T. Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study: rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemother. Pharmacol. 49, 309321 (2002).

Article PubMed Google Scholar

View post:

Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance - Nature.com